Phase 2Completed

An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CheckMate 9KD)

A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer

Sponsor
Bristol-Myers Squibb (Industry)
Enrollment
292 enrolled
Conditions
Prostate Cancer
Interventions
nivolumab; docetaxel; enzalutamide; rucaparib; prednisone
Ages
adults, older adults
Registry
NCT03338790

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to assess safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.

Primary outcomes

  • Objective Response Rate Per Prostate Cancer Clinical Trials Working Group 3 (ORR-PCWG3)
  • Prostate-Specific Antigen Response Rate (RR-PSA)

History

  1. Last registry update

  2. Study completion

  3. Results first posted

  4. Primary completion

  5. Started

  6. Registered